期刊文献+

PEA-15磷酸化状态与卵巢上皮性癌预后的相关分析 被引量:1

Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer
下载PDF
导出
摘要 目的:检测卵巢上皮性癌组织中pPEA-15-Ser104表达水平,探讨其临床意义及与卵巢上皮性癌预后的相关性。方法:选取2009年1月至2013年6月收住皖南医学院第一附属医院弋矶山医院妇产科手术治疗并经病理证实的95例原发卵巢上皮性癌,所有患者术前均未行化疗。免疫组化方法检测95例原发卵巢上皮性癌pPEA-15-Ser104的表达水平,卡方检验分析pPEA-15-Ser104表达水平在不同临床特征卵巢癌患者中差异并随访患者生存情况,采用Kaplan-Meier(K-M)方法分析不同临床特征卵巢上皮癌患者生存率差异,应用多因素Cox比例风险回归模型分析卵巢上皮性癌患者预后影响因素。结果:pPEA-15-Ser104的表达在不同组织学分级、手术病理分期、分型以及有无远处转移的卵巢上皮性癌组织中的表达比较差异均具有统计学意义(P<0.05);而在年龄、肿瘤位置、肿瘤最大径、有无淋巴结转移比较中差异无统计学意义。K-M生存分析和Cox回归分析显示,pPEA-15-Ser104高表达的卵巢癌患者预后不良,生存时间短,pPEA-15-Ser104可作为卵巢癌不良预后的独立危险因素。结论:磷酸化状态的PEA-15在卵巢上皮性癌的发展过程中发挥重要作用,高表达者预后不良,可能成为预测卵巢癌患者预后的新靶标,有望为卵巢癌患者的治疗提供重要靶点。 AIM : To detect the expression level of pPEA-15-Ser104 in epithelial ovarian carcinoma and to explore its clinical significance,and the correlation with the prognosis of epithelial ovarian carcinoma. METHODS : From January 2009 to June 2013,95 cases of primary ovarian epithelial carcinoma who were admitted to the First Affiliated Hospital of Wannan Medical College Yijishan Hospital for gynecology and obstetrics surgery and pathologically confirmed were selected. All the patients were not treated with chemotherapy before surgery.The expression levels of pPEA-15-Ser104 in 95 cases of primary ovarian epithelial carcinoma were detected by immunohistochemical method.Chi-square test was used to analyze the difference of pPEA-15-Ser104 expression in patients with ovarian cancer with different clinical characteristics.Survival status of patients with ovarian epithelial carcinoma was closely followed up after surgery .Kaplan-Meier (K-M) method was used to analyze the difference of survival rate in patients with ovarian epithelial carcinoma with different clinical characteristics.Multivariate Cox proportional risk regression model was used to analyze prognostic factors in patients with epithelial ovarian carcinoma. RESULTS :There were significant differences in the expression levels of pPEA-15-Ser104 in different histological grades,surgical and pathological stages,types and distant metastasis of ovarian epithelial carcinoma.There was no significant difference in age,tumor location,tumor maximum diameter and lymph node metastasis.K-M survival analysis and Cox regression analysis showed that the prognosis of ovarian cancer patients with high expression of pPEA-15-Ser104 was poor and the survival time was short,which could be used as an independent risk factor for poor prognosis of ovarian cancer ( P < 0.05 ). CONCLUSION : Phosphorylated PEA-15 plays an important role in the development of ovarian epithelial carcinoma.The prognosis of the patients with high expression is poor.It may become a new target to predict the prognosis of ovarian cancer patients,and it is expected to provide an important target for the treatment of ovarian cancer patients.
作者 方川川 倪观太 金兰 刘记 刘晓庆 乔春 罗永红 FANG Chuanchuan;NI Guantai;JIN Lan;LIU Ji;LIU Xiaoqing;QIAO Chun;LUO Yonghong(Wannan Medical College,the First Affiliated Hospital of Wannan Medical College,Wuhu 241001,Anhui,China;Department of Obstetrics and Gynecology,the First Affiliated Hospital of Wannan Medical College,Wuhu 241001,Anhui,China)
出处 《中国临床药理学与治疗学》 CAS CSCD 2019年第5期523-528,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 安徽省高等学校自然科学研究项目(KJ2017A265)
关键词 卵巢上皮性癌 pPEA-15-Ser104 预后 免疫组化 epithelial ovarian cancer pPEA-15-Ser104 prognosis immunohistochemistry
  • 相关文献

参考文献4

二级参考文献27

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 2Richard G. Moore,Shannon MacLaughlan,Robert C. Bast.Current state of biomarker development for clinical application in epithelial ovarian cancer[J].Gynecologic Oncology.2009(2)
  • 3Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
  • 4Pitti R M,Marsters S A,Ruppert S,et al.Induction of apoptosis by Apo-2 ligand,a new member of the tumor necrosis factor cytokine family[J].Biol Chem,1996,271(22):12687-12690.
  • 5Tecchio C,Huber V,Scapini P,et al.IFN-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand ( TRAIL/Apo-2 ligand ) displaying apoptotic activity on leukemic cells[J].Blood,2004,103(10):3837-3844.
  • 6Lane D,Cartier A,Rancourt C,et al.Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt path way [J].Int J Gynecol Cancer,2008,18(4):670-676.
  • 7Matei D,Fang F,Shen C,et al.Epigenetic resensitization to platinum in ovarian cancer[J].Cancer Res,2012,72(72):2197-2205.
  • 8Jo M,Kim T H,Seol D W,et al.Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand[J].Nat Med,2000,6(5):564-567.
  • 9Pritzker L B,Scatena M,Giachelli C M.The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival[J].Mol Biol Cell,2004,15(6):2834-2841.
  • 10Wang F,Zhou J,Xie X,et al.Involvement of SRPKl in cisplatin resistance related to long non-coding RNA UCAl in human ovarian cancer cells[J].Neoplasma,2015,62(3):432-438.

共引文献3

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部